Last updated: February 13, 2026
Overview
NDC 00054-0064 corresponds to a specific pharmaceutical product, which is essential to identify before analyzing market dynamics. This unique identifier is linked to Prolia (denosumab), marketed by Amgen. Prolia is a monoclonal antibody used to treat osteoporosis and other bone-related conditions.
Market Size and Demand Drivers
Prolia primarily targets osteoporosis, a condition affecting over 200 million globally. The U.S. market alone accounts for approximately 70% of global osteoporosis treatment sales, equating to nearly $10 billion annually (IQVIA, 2022). Factors influencing demand include:
- Increasing aging population in developed markets.
- Growing awareness about osteoporosis.
- Expanding indications such as metastatic bone disease and certain cancers.
- Preference for biologics over traditional therapies.
Global osteoporosis drug market is projected to reach $14 billion by 2025, with biologics like denosumab accounting for a significant share (Research and Markets, 2023).
Competitive Landscape
Prolia's main competitors include:
- Bisphosphonates (e.g., alendronate, zoledronic acid)
- Serum Faltate inhibitors (e.g., romosozumab)
- Other monoclonal antibodies targeting RANKL pathway
Market share is approximately 35-40% among osteoporosis therapeutics, with ongoing competition from newer agents.
Pricing and Reimbursement Environment
In the U.S., Prolia's wholesale acquisition cost (WAC) is approximately $2,100 per dose. Treatment involves two doses per year, translating into roughly $4,200 annually per patient (CMS, 2023). Price adjustments depend on:
- Negotiations with payers.
- Value-based agreements.
- Patent protections and biosimilar entries.
In Europe, prices are lower, typically around €1,500–€2,000 per year, varying by country and reimbursement policies.
Regulatory and Patent Status
Prolia holds patent protection until at least 2029. Biosimilar competition is imminent, with several candidates under development, expected to enter the market by 2025-2026. Patent expirations and biosimilar approval will influence pricing and market share.
Price Projection Scenarios
| Scenario |
Year |
Anticipated Price per Year |
Rationale |
| Base |
2023 |
$4,200 |
Current pricing, stable reimbursement policies |
| Bear |
2025 |
$2,500–$3,000 |
Biosimilar entry causing price erosion |
| Bull |
2027 |
$4,000–$4,500 |
Patent extension, new indications, market retention |
Revenue Projections
Assuming the following:
- 700,000 patients on therapy globally in 2023.
- Steady growth at 3% annually.
- Market share maintained or slightly increased.
Estimated global revenues:
- 2023: ~$2.94 billion.
- 2025 (post-biosimilar entry): ~$2.1 billion.
- 2027: ~$2.7 billion, assuming price recovery and market retention.
Risks and Opportunities
Risks:
- Biosimilar competition diminishing revenue.
- Regulatory hurdles in emerging markets.
- Price pressure due to healthcare cost containment.
Opportunities:
- Approval of new indications enhances market size.
- Expansion into oncology and metastatic bone disease.
- Cost reduction strategies for hospitals and insurers.
Key Takeaways
NDC 00054-0064 (Prolia) is a leading osteoporosis biologic with significant current sales, driven by aging populations and expanding indications. Patent expiry and biosimilar development pose imminent threats to pricing and market share. Price projections indicate potential declines post-biosimilar entry, with partial recovery through expanded indications and market penetration. Market size remains substantial, providing ongoing revenue opportunities amidst competitive pressures.
FAQs
-
What challenges could biosimilars pose to Prolia's pricing?
Biosimilars can reduce prices significantly, potentially by 30-50%, leading to revenue declines and increased price competition.
-
How does patent expiration impact Prolia's market?
Patent expiry around 2029 opens opportunities for biosimilar competitors, which can erode market share and lower prices.
-
Are new indications for Prolia expected to influence revenue?
Yes, approvals for additional uses, such as metastatic bone disease, can expand the patient base and boost revenue.
-
How does global pricing vary for Prolia?
In the U.S., it costs approximately $4,200 annually; in Europe, prices range €1,500–€2,000 annually, depending on country policies.
-
What is the outlook for Prolia's market share?
Maintaining market share depends on biosimilar market penetration, payer negotiations, and innovative extensions to its label.
Sources
[1] IQVIA Reports, 2022
[2] Research and Markets, 2023
[3] Centers for Medicare & Medicaid Services (CMS), 2023
